Scilex Holding Company (Scilex), a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc. announced the appointment of Laura Hamill, an accomplished pharmaceutical and biotechnology executive, to its Board of Directors. Ms. Hamill brings to the Scilex board more than three decades of experience in the biopharma industry, serving most recently as Executive Vice President, Worldwide Commercial Operations at Gilead Sciences, Inc.